We also have obtained and analyzed the TCGA data using the cBioportal Tool (http://www.cbioportal.org/) and found that the prevalent co-mutations of KRAS mutant NSCLC patients are TTN(51.19%), RYR2(45.80%), MUC16(42.78%%), CSMD3(40.18%), LRP1B(39.55%), TP53(39.38%), USH2A(38.75%), ZFHX4(37.39%), SPTA1(32.89%), FLG(30.74%). Here, SPTA1 is linked to non-small cell lung carcinoma.